Corbus Pharmaceuticals
CRBP
14 hedge funds and large institutions have $9.54M invested in Corbus Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 14 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$5.87M |
| 2 |
PA
Perceptive Advisors
New York
|
+$2.92M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.12M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$175K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$123K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KCM
1
Knoll Capital Management
Miami,
Florida
| $5.39M | +$5.87M | +58,333 | New |
|
|
PA
2
Perceptive Advisors
New York
| $2.68M | +$2.92M | +29,000 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $1.03M | +$1.12M | +11,124 | New |
|
|
BFA
4
BlackRock Fund Advisors
San Francisco,
California
| $161K | +$175K | +1,745 | New |
|
|
DCM
5
DAFNA Capital Management
Los Angeles,
California
| $113K | +$123K | +1,220 | New |
|
|
VKH
6
Virtu KCG Holdings
New York
| $85K | +$92.3K | +918 | New |
|
7
Northern Trust
Chicago,
Illinois
| $34K | +$36.9K | +367 | New |
|
8
Morgan Stanley
New York
| $16K | +$17.9K | +178 | New |
|
|
BIM
9
BlackRock Investment Management
Wilmington,
Delaware
| $10K | +$10.4K | +103 | New |
|
|
BIT
10
BlackRock Institutional Trust
San Francisco,
California
| $10K | +$10.8K | +107 | New |
|
|
BA
11
BlackRock Advisors
Wilmington,
Delaware
| $6K | +$6.54K | +65 | New |
|
12
UBS Group
Zurich,
Switzerland
| $6K | +$6.64K | +66 | New |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| $3K | +$3.12K | +31 | New |
|
14
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$1.71K | +17 | New |
|
CRBP Hedge Fund Activity: Q2 2015 in Review
14 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2015, worth a combined $9.54M.
Buyers outnumbered sellers: 14 funds opened new CRBP positions and 0 closed out — a net gain of 14 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Knoll Capital Management, opening a new position worth an estimated $5.87M.
- 14 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $9.54M of Corbus Pharmaceuticals stock for Q2 2015.
- 14 funds opened new Corbus Pharmaceuticals positions in Q2 2015 and 0 closed out, a net change of +14 holders.
- The largest Corbus Pharmaceuticals buyer in Q2 2015 was Knoll Capital Management, an estimated $5.87M added.
Based on aggregated 13F filings for Q2 2015.